Literature DB >> 3910386

Ceftriaxone: a third-generation cephalosporin.

M C Nahata, W J Barson.   

Abstract

Ceftriaxone is a new third-generation cephalosporin with excellent activity against many gram-negative, and reasonable activity against most gram-positive microorganisms. Clinical studies have demonstrated its efficacy and safety in patients with bacterial meningitis; respiratory tract, urinary tract, soft tissue, bone and joint infections; and gonorrhea. Ceftriaxone has been well tolerated except for diarrhea, which in most cases has not required a change in therapy. The long elimination half-life of ceftriaxone has allowed twice- and once-daily administration, the latter potentially resulting in substantial cost savings. Because of its documented efficacy, safety, and convenient dosing schedule, ceftriaxone may become the preferred third-generation cephalosporin for the treatment of a variety of serious infections.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3910386     DOI: 10.1177/106002808501901203

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  4 in total

1.  The role of Gr-1(+) cells and tumour necrosis factor-α signalling during Clostridium difficile colitis in mice.

Authors:  Andrew J McDermott; Kathryn E Higdon; Ryan Muraglia; John R Erb-Downward; Nicole R Falkowski; Roderick A McDonald; Vincent B Young; Gary B Huffnagle
Journal:  Immunology       Date:  2015-04       Impact factor: 7.397

Review 2.  Clinical pharmacokinetics of ceftriaxone.

Authors:  J H Yuk; C H Nightingale; R Quintiliani
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

3.  Gut Microbiome in a Russian Cohort of Pre- and Post-Cholecystectomy Female Patients.

Authors:  Irina Grigor'eva; Tatiana Romanova; Natalia Naumova; Tatiana Alikina; Alexey Kuznetsov; Marsel Kabilov
Journal:  J Pers Med       Date:  2021-04-12

4.  Quantifying antibiotic impact on within-patient dynamics of extended-spectrum beta-lactamase resistance.

Authors:  Rene Niehus; Esther van Kleef; Yin Mo; Agata Turlej-Rogacka; Christine Lammens; Yehuda Carmeli; Herman Goossens; Evelina Tacconelli; Biljana Carevic; Liliana Preotescu; Surbhi Malhotra-Kumar; Ben S Cooper
Journal:  Elife       Date:  2020-05-07       Impact factor: 8.140

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.